Health Catalyst (HCAT) to Release Earnings on Wednesday

Health Catalyst (NASDAQ:HCAT) is projected to post its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Health Catalyst to post earnings of $0.10 per share and revenue of $73.9880 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:00 PM ET.

Health Catalyst Stock Down 6.0%

Shares of HCAT opened at $1.73 on Wednesday. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.46. The business has a fifty day moving average of $2.28 and a 200 day moving average of $2.74. The company has a market cap of $122.36 million, a PE ratio of -1.09 and a beta of 1.73. Health Catalyst has a 52-week low of $1.72 and a 52-week high of $5.56.

Analysts Set New Price Targets

Several research firms have recently issued reports on HCAT. Wells Fargo & Company lowered their target price on shares of Health Catalyst from $6.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. William Blair restated an “outperform” rating on shares of Health Catalyst in a research report on Tuesday, November 11th. Citigroup reduced their price target on Health Catalyst from $3.25 to $2.75 and set a “neutral” rating on the stock in a report on Friday, January 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Health Catalyst in a research report on Monday, December 29th. Finally, UBS Group reiterated an “outperform” rating on shares of Health Catalyst in a research report on Tuesday, November 11th. Five research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $4.32.

Insider Buying and Selling at Health Catalyst

In other news, General Counsel Benjamin Landry sold 27,425 shares of the firm’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $2.64, for a total transaction of $72,402.00. Following the transaction, the general counsel owned 100,000 shares in the company, valued at approximately $264,000. This trade represents a 21.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Julie Larson-Green sold 47,997 shares of the company’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $2.67, for a total transaction of $128,151.99. Following the completion of the sale, the director directly owned 73,573 shares of the company’s stock, valued at approximately $196,439.91. This trade represents a 39.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Health Catalyst

Institutional investors have recently bought and sold shares of the business. Cresset Asset Management LLC purchased a new stake in Health Catalyst during the second quarter worth $39,000. Focus Partners Wealth bought a new position in shares of Health Catalyst in the 1st quarter worth $46,000. BNP Paribas Financial Markets lifted its stake in shares of Health Catalyst by 71.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock worth $47,000 after purchasing an additional 6,832 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its position in Health Catalyst by 52.4% during the third quarter. Dynamic Technology Lab Private Ltd now owns 29,630 shares of the company’s stock valued at $84,000 after purchasing an additional 10,183 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Health Catalyst in the third quarter valued at about $90,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.